- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Dana Goldman Discusses Determing Value for Breakthrough Therapies
Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.
Dana Goldman, PhD, suggests that value for breakthrough therapies is most often associated with health benefits, health economics, and outcomes research; however, there are other sources of value that have not been taken into account yet.
For example, there is value in curing a disease because it not only impacts the patient but also anyone the patient may have come in contact with, including caregivers and family members.
“We need to figure out how all these ancillary sources of value are affected and in particular who should pay for them as well,” Dr Goldman says.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
